Status:
UNKNOWN
Evaluation of Cerebral Small Vessel Disease in Patient With Primary Aldosteronism
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Evaluation of Cerebral Small Vessel Disease in Patient With Primary Aldosteronism
Eligibility:
All Genders
20-90 years
Phase:
PHASE1
Brief Summary
Hypertension is known to be the major risk factor for stroke. The most common cause of secondary hypertension, primary aldosteronism (PA), is characterized by the excessive secretion of aldosterone an...
Eligibility Criteria
Inclusion
- age between 20-90 years-old
- patient with primary aldosteronism or healthy control
- consciousness clear
- willing to receive brain MRI
Exclusion
- renal failure or Creatinine \> 2mg/dl
- coagulopathy or hepatic insufficiency
- unstable vital sign under inotropic agents
- pregnancy
- metal implant or cardiac pacemaker
- major brain surgery
Key Trial Info
Start Date :
January 25 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03821571
Start Date
January 25 2019
End Date
December 31 2020
Last Update
January 30 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bei-Hu Branch, National Taiwan University Hospital
Taipei, Taiwan, 10048